C81.2A
Mixed cellularity Hodgkin lymphoma, in remission
Clinical Classification Guidelines
Medical Intelligence & Overview
Mixed Cellularity Hodgkin Lymphoma is a subtype of Hodgkin lymphoma, a type of cancer that originates in the lymphatic system. When this disease enters remission, it indicates that signs and symptoms of the cancer have decreased or disappeared following treatment. This condition, classified under ICD-10 code C81.2A, involves a specific cellular makeup of the lymphoma, characterized by a mixture of different cell types within the lymph nodes. Remission suggests that treatments such as chemotherapy or radiation therapy have been effective, and ongoing monitoring is essential for ensuring the disease does not return.
Causes & Symptoms
Clinical Causes: Genetic factors that predispose individuals to lymphatic cancers Previous exposure to certain viruses, such as Epstein-Barr virus (EBV) History of immune system suppression or disorders Environmental exposures, although specific environmental causes are not well established Family history of Hodgkin lymphoma or other lymphatic cancers
Key Symptoms: Swollen lymph nodes in the neck, armpits, or groin, often painless Persistent fever without obvious cause Night sweats that may drench clothing and bedding Unexplained weight loss Fatigue and weakness Itching skin, without apparent reason Persistent cough or trouble breathing if chest lymph nodes are involved
Diagnostic & Treatment
Diagnosis Path: Diagnosing Mixed Cellularity Hodgkin Lymphoma involves a combination of physical examinations, imaging tests, and biopsies. Key diagnostic steps include: - Conducting a physical exam to check for swollen lymph nodes - Performing imaging studies such as CT scans, PET scans, or X-rays to locate affected areas - Obtaining a biopsy of the lymph nodes or affected tissues where tissue samples are examined under a microscope for characteristic cancer cells and cellular makeup - Blood tests to assess overall health and organ function - Additional tests to stage the disease and determine the extent of involvement Once diagnosed, ongoing assessments are crucial to confirm remission status and monitor for potential relapse.
Treatment Protocols: Treatment for Mixed Cellularity Hodgkin Lymphoma typically involves chemotherapy, radiation therapy, or a combination of both. This approach aims to eliminate cancer cells, induce remission, and manage symptoms. Specific treatment strategies include: - Chemotherapy regimens such as ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine), often administered in cycles - Radiation therapy targeted at affected lymph nodes or regions - Immunotherapy or targeted therapy in certain cases - Supportive care to manage side effects For patients in remission, regular follow-up appointments, imaging, and blood tests are critical to monitor for disease recurrence and maintain health. Long-term monitoring also helps address potential late effects of treatment.
Clinical Advice & FAQs
Billing Guidance
Is C81.2A a billable ICD-10 code?
Yes, C81.2A is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.2A?
Clinical documentation must specify the nature of Mixed cellularity Hodgkin lymphoma, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
